9 Sept 2023 • Anti-CD3 monoclonal antibodies have shown promising outcomes in improving the management of the Type 1 Diabetes Mellitus (T1D), according to recent studies.

In late 2022, Teplizumab was approved by the US FDA as the first disease-modifying agent for the treatment of T1D.

To evaluate the clinical evidence regarding the efficacy of anti-CD3 monoclonal antibodies in the prevention and treatment of type 1 diabetes, a meta- analysis was performed.

A comprehensive search of literature was conducted up to identify relevant randomized controlled trials up to late 2022.

11 randomized controlled trials involving 1397 participants were studied in this review, and the results revealed the following:

• Anti-CD3 monoclonal antibody treatment significantly increased the C-peptide concentration, as compared with placebo.
• The patients' insulin intake was significantly reduced with anti-CD3 monoclonal antibodies. - However, no significant effect on glycated haemoglobin concentration was observed.

These findings suggest that anti-CD3 monoclonal antibody treatment increases endogenous insulin production and improves the lifestyle of T1D patients by decreasing insulin dosage.

Source: Diabetes, Obesity and Metabolism | Read full story"